Browse MCF2

Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm ; SUBCELLULAR LOCATION: Isoform 1: Membrane.; SUBCELLULAR LOCATION: Isoform 3: Membrane. Note=Colocalizes with CDC42 to plasma membrane.
Domain PF13716 Divergent CRAL/TRIO domain
PF00169 PH domain
PF00621 RhoGEF domain
Function

Guanine nucleotide exchange factor (GEF) that modulates the Rho family of GTPases. Promotes the conversion of some member of the Rho family GTPase from the GDP-bound to the GTP-bound form. Isoform 1 exhibits no activity toward RHOA, RAC1 or CDC42. Isoform 2 exhibits decreased GEF activity toward CDC42. Isoform 3 exhibits a weak but significant activity toward RAC1 and CDC42. Isoform 4 exhibits significant activity toward RHOA and CDC42. The truncated DBL oncogene is active toward RHOA, RAC1 and CDC42.

> Gene Ontology
 
Biological Process GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0016358 dendrite development
GO:0035023 regulation of Rho protein signal transduction
GO:0046578 regulation of Ras protein signal transduction
GO:0051056 regulation of small GTPase mediated signal transduction
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005089 Rho guanyl-nucleotide exchange factor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE
R-HSA-416482: G alpha (12/13) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-193648: NRAGE signals death through JNK
R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-194315: Signaling by Rho GTPases
R-HSA-166520: Signalling by NGF
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MCF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MCF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MCF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3640.422
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9180.246
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0570.924
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9430.286
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2050.407
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6360.657
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3620.683
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1180.931
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7490.621
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3020.07
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MCF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277329.62.726.90.000357
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275929.63.426.20.00115
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MCF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MCF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MCF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MCF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MCF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MCF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMCF2
NameMCF.2 cell line derived transforming sequence
Aliases DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL
Chromosomal LocationXq26.3-q27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MCF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.